Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA/CD19 CAR-T in R/R Autoimmune Diseases
NCT06428188Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BCMA/CD19 CAR-T cells in autoimmune disease, systemic lupus erythematosus (SLE), Sjogren's syndrome, sponsored by Essen BioTech. Started May 2024; status: recruiting.
02
Drugs
BCMA/CD19 CAR-T cells
03
Conditions
autoimmune diseasesystemic lupus erythematosus (SLE)Sjogren's syndrome
Beyond the preview
Go deeper on NCT06428188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428188.